SLAMF6 deficiency augments tumor killing and skews towards an effector phenotype revealing it as a new T cell checkpoint
E. Hajaj, G. Eisenberg, S. Klein, S. Frankenburg, S. Merims, I. Ben David, T. Eisenhaure, S. E. Henrickson, A. C. Villani, N. Hacohen, N. Abudi, R. Abramovich, J. E. Cohen, T. Peretz, A. Veillette, M. Lotem
This study shows that SLAMF6 deficiency enhances T cell tumor-killing ability and shifts T cells toward an effector phenotype, suggesting SLAMF6 as a new immune checkpoint.
bioRxiv · Oct 31, 2019Physiology